… of chronic myeloid leukemia (CML). Imatinib is a relatively specific inhibitor of BCR-ABL,
the … characteristic of CML and some acute lymphocytic leukemias. The fusion of BCR-ABL …

… influence the interaction with clinically approved AML inhibitors used to treat the AML. …
inhibitors at the atomic level is still unknown. In this manuscript, we have investigated the structural …

… inhibition of FLT3 kinase activity, selectively kill leukemic cells harboring mutant FLT3 with
no apparent effect … However, the structural composition of the second-generation inhibitors …

… Next, we analyzed the effects of K00135 on the growth of leukemic blasts from five patients
with newly diagnosed AML. When cultured in methylcellulose, the cells from AML patients …

… of protein kinase inhibitors. Here, we discuss our experience in the preclinical and clinical
development of a Bcr-Abl inhibitor as a therapeutic agent for chronic myelogenous leukemia (…

… Staurosporine, a microbial alkaloid, is a strong inhibitor of protein kinases. The effects of …
studied and compared with the effects of this drug on human lymphocytic leukemic MOI I-4 cells. …

… inhibitor endowed with cytotoxic effects against AML cell lines [78] and displaying synergistic
effect on Bcr-Abl leukemia … Another specific MEK inhibitor is PD184352 (Fig. 19), which in …

… of some types of pediatric leukemia and testicular cancer, the effect of such chemotherapeutic
… 3.1) as the first BCR-ABL1 kinase inhibitor for the treatment for chronic myeloid leukemia (…

… inhibitors treated leukemia cell lines showed that proteasome inhibitors were good inducers
of leukemia cells … Transformed cells are much more sensitive to proteasome inhibition than …

… was extracted by our standard method4 using leukemia L1210 assay.5 … We are actively
pursuing the synthesis of camptothecin and simpler analogs and the effects of structure …